EGF receptor variant III as a target antigen for tumor immunotherapy

References

• Minino AM, Heron MP, Murphy SL, Kochanek KD. Deaths: final data for 2004. Natl Vital Stat. Rep.55(19), 1–119 (2007).
   PubMedGoogle Scholar
• Salomon DS, Brandt R, Ciardiello F, Normanno N. Epidermal growth factor-related peptides and their receptors in human malignancies. Crit. Rev. Oncol. Hematol.19(3), 183–232 (1995).
   PubMed Web of Science ®Google Scholar
• Citri A, Yarden Y. EGF-ERBB signalling: towards the systems level. Nat .Rev. Mol. Cell Biol.7(7), 505–516 (2006).
   PubMed Web of Science ®Google Scholar
• Hynes NE, Lane HA. ERBB receptors and cancer: the complexity of targeted inhibitors. Nat. Rev. Cancer5(5), 341–354 (2005).
   PubMed Web of Science ®Google Scholar
• Wong AJ, Bigner SH, Bigner DD, Kinzler KW, Hamilton SR, Vogelstein B. Increased expression of the epidermal growth factor receptor gene in malignant gliomas is invariably associated with gene amplification. Proc. Natl Acad. Sci. USA84(19), 6899–6903 (1987).
   PubMed Web of Science ®Google Scholar
• Libermann TA, Nusbaum HR, Razon N et al. Amplification, enhanced expression and possible rearrangement of EGF receptor gene in primary human brain tumours of glial origin. Nature313(5998), 144–147 (1985).
   PubMed Web of Science ®Google Scholar
• Ciardiello F, Tortora G. EGFR antagonists in cancer treatment. N. Engl. J. Med.358(11), 1160–1174 (2008).
   PubMed Web of Science ®Google Scholar
• Humphrey PA, Wong AJ, Vogelstein B et al. Anti-synthetic peptide antibody reacting at the fusion junction of deletion-mutant epidermal growth factor receptors in human glioblastoma. Proc. Natl Acad. Sci. USA87(11), 4207–4211 (1990).
   PubMed Web of Science ®Google Scholar
• Wong AJ, Ruppert JM, Bigner SH et al. Structural alterations of the epidermal growth factor receptor gene in human gliomas. Proc. Natl Acad. Sci. USA89(7), 2965–2969 (1992).
   PubMed Web of Science ®Google Scholar
• Fernandes H, Cohen S, Bishayee S. Glycosylation-induced conformational modification positively regulates receptor–receptor association: a study with an aberrant epidermal growth factor receptor (EGFRvIII/δEGFR) expressed in cancer cells. J. Biol. Chem.276(7), 5375–5383 (2001).
   PubMed Web of Science ®Google Scholar
• Antonyak MA, Moscatello DK, Wong AJ. Constitutive activation of c-Jun N-terminal kinase by a mutant epidermal growth factor receptor. J. Biol. Chem.273(5), 2817–2822 (1998).
   PubMed Web of Science ®Google Scholar
• Moscatello DK, Holgado-Madruga M, Emlet DR, Montgomery RB, Wong AJ. Constitutive activation of phosphatidylinositol 3-kinase by a naturally occurring mutant epidermal growth factor receptor. J. Biol. Chem.273(1), 200–206 (1998).
   PubMed Web of Science ®Google Scholar
• Galanis E, Buckner J, Kimmel D et al. Gene amplification as a prognostic factor in primary and secondary high-grade malignant gliomas. Int. J. Oncol.13(4), 717–724 (1998).
   PubMed Web of Science ®Google Scholar
• Newcomb EW, Cohen H, Lee SR et al. Survival of patients with glioblastoma multiforme is not influenced by altered expression of p16, p53, EGFR, MDM2 or Bcl-2 genes. Brain Pathol.8(4), 655–667 (1998).
   PubMed Web of Science ®Google Scholar
• Waha A, Baumann A, Wolf HK et al. Lack of prognostic relevance of alterations in the epidermal growth factor receptor-transforming growth factor-α pathway in human astrocytic gliomas. J. Neurosurg.85(4), 634–641 (1996).
   Google Scholar
• Zhu A, Shaeffer J, Leslie S, Kolm P, El Mahdi AM. Epidermal growth factor receptor: an independent predictor of survival in astrocytic tumors given definitive irradiation. Int. J. Radiat. Oncol. Biol. Phys.34(4), 809–815 (1996).
   PubMed Web of Science ®Google Scholar
• Etienne MC, Formento JL, Lebrun-Frenay C et al. Epidermal growth factor receptor and labeling index are independent prognostic factors in glial tumor outcome. Clin. Cancer Res.4(10), 2383–2390 (1998).
   PubMed Web of Science ®Google Scholar
• Smith JS, Tachibana I, Passe SM et al. PTEN mutation, EGFR amplification, and outcome in patients with anaplastic astrocytoma and glioblastoma multiforme. J. Natl Cancer Inst.93(16), 1246–1256 (2001).
   PubMed Web of Science ®Google Scholar
• Heimberger AB, Hlatky R, Suki D et al. Prognostic effect of epidermal growth factor receptor and EGFRvIII in glioblastoma multiforme patients. Clin. Cancer Res.11(4), 1462–1466 (2005).
   PubMed Web of Science ®Google Scholar
• Heimberger AB, Suki D, Yang D, Shi W, Aldape K. The natural history of EGFR and EGFRvIII in glioblastoma patients. J. Transl. Med.3, 38 (2005).
   PubMed Web of Science ®Google Scholar
• Moscatello DK, Holgado-Madruga M, Godwin AK et al. Frequent expression of a mutant epidermal growth factor receptor in multiple human tumors. Cancer Res.55(23), 5536–5539 (1995).
   PubMed Web of Science ®Google Scholar
• Garcia dP, I, Adams GP, Sundareshan P et al. Expression of mutated epidermal growth factor receptor by non-small cell lung carcinomas. Cancer Res.53(14), 3217–3220 (1993).
   PubMedGoogle Scholar
• Cunningham MP, Essapen S, Thomas H et al. Coexpression, prognostic significance and predictive value of EGFR, EGFRvIII and phosphorylated EGFR in colorectal cancer. Int. J. Oncol.27(2), 317–325 (2005).
   PubMed Web of Science ®Google Scholar
• Ge H, Gong X, Tang CK. Evidence of high incidence of EGFRvIII expression and coexpression with EGFR in human invasive breast cancer by laser capture microdissection and immunohistochemical analysis. Int. J. Cancer98(3), 357–361 (2002).
   PubMed Web of Science ®Google Scholar
• Purev E, Cai D, Miller E et al. Immune responses of breast cancer patients to mutated epidermal growth factor receptor (EGF-RvIII, d EGF-R, and de2-7 EGF-R). J. Immunol.173(10), 6472–6480 (2004).
   PubMed Web of Science ®Google Scholar
• Sok JC, Coppelli FM, Thomas SM et al. Mutant epidermal growth factor receptor (EGFRvIII) contributes to head and neck cancer growth and resistance to EGFR targeting. Clin. Cancer Res.12(17), 5064–5073 (2006).
   PubMed Web of Science ®Google Scholar
• Olapade-Olaopa EO, Moscatello DK, MacKay EH et al. Evidence for the differential expression of a variant EGF receptor protein in human prostate cancer. Br. J. Cancer82(1), 186–194 (2000).
   PubMed Web of Science ®Google Scholar
• Wikstrand CJ, Hale LP, Batra SK et al. Monoclonal antibodies against EGFRvIII are tumor specific and react with breast and lung carcinomas and malignant gliomas. Cancer Res.55(14), 3140–3148 (1995).
   PubMed Web of Science ®Google Scholar
• Moscatello DK, Ramirez G, Wong AJ. A naturally occurring mutant human epidermal growth factor receptor as a target for peptide vaccine immunotherapy of tumors. Cancer Res.57(8), 1419–1424 (1997).
   PubMed Web of Science ®Google Scholar
• Harris JR, Markl J. Keyhole limpet hemocyanin (KLH): a biomedical review. Micron30(6), 597–623 (1999).
   PubMed Web of Science ®Google Scholar
• Heimberger AB, Crotty LE, Archer GE et al. Epidermal growth factor receptor VIII peptide vaccination is efficacious against established intracerebral tumors. Clin. Cancer Res.9(11), 4247–4254 (2003).
   PubMed Web of Science ®Google Scholar
• Ciesielski MJ, Kazim AL, Barth RF, Fenstermaker RA. Cellular antitumor immune response to a branched lysine multiple antigenic peptide containing epitopes of a common tumor-specific antigen in a rat glioma model. Cancer Immunol. Immunother.54(2), 107–119 (2005).
   PubMedGoogle Scholar
• Heimberger AB, Archer GE, Crotty LE et al. Dendritic cells pulsed with a tumor-specific peptide induce long-lasting immunity and are effective against murine intracerebral melanoma. Neurosurgery50(1), 158–164 (2002).
   PubMed Web of Science ®Google Scholar
• Wu AH, Xiao J, Anker L et al. Identification of EGFRvIII-derived CTL epitopes restricted by HLA A0201 for dendritic cell based immunotherapy of gliomas. J. Neurooncol.76(1), 23–30 (2006).
   PubMed Web of Science ®Google Scholar
• Archer G, Bigner D, Friedman A et al. Dendritic cell vaccine for intracranial tumors 1 (DC VICTORI Trial). Presented at: 2004 Society of Neuro-oncology Meeting. Ontario, Canada, 18–24 November 2004 (Abstract).
   Google Scholar
• Sampson JH, Archer GE, Mitchell DA, Heimberger AB, Bigner DD. Tumor-specific immunotherapy targeting the EGFRvIII mutation in patients with malignant glioma. Semin. Immunol. DOI: 10.1016/j.smim.2008.04.001 (2008) (Epub ahead of print).
   Google Scholar
• Heimberger AB, Hussain SF, Aldape K et al. Tumor-specific peptide vaccination in newly-diagnosed patients with GBM. J. Clin. Oncol.24(18 Suppl.), 2529 (2006).
   Google Scholar
• Sampson JH, Aldape K, Gilbert S et al. Temozolomide as a vaccine adjuvant in GBM. J. Clin. Oncol.25(18 Suppl.) 2020 (2007).
   Google Scholar
• Stupp R, Mason WP, van den Bent MJ et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N. Engl. J. Med.352(10), 987–996 (2005).
   PubMed Web of Science ®Google Scholar
• Emens LA, Reilly RT, Jaffee EM. Cancer vaccines in combination with multimodality therapy. Cancer Treat. Res.123, 227–245 (2005).
   PubMedGoogle Scholar
• Sampson JH, Archer GE, Bigner DD et al. Effect of EGFRvIII-targeted vaccine (CDX-110) on immune response and TTP when given with simultaneous standard and continuous temozolomide in patients with GBM. J. Clin. Oncol.26(Suppl.) (2008) (Abstract 2011).
   Google Scholar
• Sonabend AM, Dana K, Lesniak MS. Targeting epidermal growth factor receptor variant III: a novel strategy for the therapy of malignant glioma. Expert Rev. Anticancer Ther.7(12 Suppl.), S45–S50 (2007).
   PubMed Web of Science ®Google Scholar
• Sampson JH, Crotty LE, Lee S et al. Unarmed, tumor-specific monoclonal antibody effectively treats brain tumors. Proc. Natl Acad. Sci. USA97(13), 7503–7508 (2000).
   PubMed Web of Science ®Google Scholar
• Wikstrand CJ, Hale LP, Batra SK et al. Monoclonal antibodies against EGFRvIII are tumor specific and react with breast and lung carcinomas and malignant gliomas. Cancer Res.55(14), 3140–3148 (1995).
   PubMed Web of Science ®Google Scholar
• Modjtahedi H, Moscatello DK, Box G et al. Targeting of cells expressing wild-type EGFR and type-III mutant EGFR (EGFRvIII) by anti-EGFR MAb ICR62: a two-pronged attack for tumour therapy. Int. J. Cancer105(2), 273–280 (2003).
   PubMed Web of Science ®Google Scholar
• Li D, Ji H, Zaghlul S et al. Therapeutic anti-EGFR antibody 806 generates responses in murine de novo EGFR mutant-dependent lung carcinomas. J. Clin. Invest.117(2), 346–352 (2007).
   PubMed Web of Science ®Google Scholar
• Ochiai H, Archer GE, Herndon JE et al. EGFRvIII-targeted immunotoxin induces antitumor immunity that is inhibited in the absence of CD4+ and CD8+ T cells. Cancer Immunol. Immunother.57(1), 115–121 (2008).
   PubMed Web of Science ®Google Scholar
• Mamot C, Drummond DC, Noble CO et al. Epidermal growth factor receptor-targeted immunoliposomes significantly enhance the efficacy of multiple anticancer drugs in vivo. Cancer Res.65(24), 11631–11638 (2005).
   PubMed Web of Science ®Google Scholar
• Kuan CT, Wikstrand CJ, Bigner DD. EGF mutant receptor vIII as a molecular target in cancer therapy. Endocr. Relat. Cancer8(2), 83–96 (2001).
   PubMed Web of Science ®Google Scholar
• Yang W, Wu G, Barth RF et al. Molecular targeting and treatment of composite EGFR and EGFRvIII-positive gliomas using boronated monoclonal antibodies. Clin. Cancer Res.14(3), 883–891 (2008).
   PubMedGoogle Scholar
• Trembath DG, Lal A, Kroll DJ, Oberlies NH, Riggins GJ. A novel small molecule that selectively inhibits glioblastoma cells expressing EGFRvIII. Mol. Cancer6, 30 (2007).
   Google Scholar
• Voelzke WR, Petty WJ, Lesser GJ. Targeting the epidermal growth factor receptor in high-grade astrocytomas. Curr. Treat. Options Oncol. (1), 23–31 (2008).
   Google Scholar
• Mellinghoff IK, Wang MY, Vivanco I et al. Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors. N. Engl. J. Med.353(19), 2012–2024 (2005).
   PubMed Web of Science ®Google Scholar
• Haas-Kogan DA, Prados MD, Tihan T et al. Epidermal growth factor receptor, protein kinase B/Akt, and glioma response to erlotinib. J. Natl Cancer Inst.97(12), 880–887 (2005).
   PubMed Web of Science ®Google Scholar
• van den Bent MJ, Brandes A, Rampling R et al. Randomized Phase II trial of erlotinib versus temozolomide or BCNU in recurrent glioblastoma multiforme: EORTC 26034. J. Clin. Oncol.25(18 Suppl.) (2007).
   Google Scholar
• Lassman AB, Rossi MR, Raizer JJ et al. Molecular study of malignant gliomas treated with epidermal growth factor receptor inhibitors: tissue analysis from North American Brain Tumor Consortium trials 01–03 and 00–01. Clin. Cancer Res.11(21), 7841–7850 (2005).
   PubMed Web of Science ®Google Scholar
• Halatsch ME, Schmidt U, Behnke-Mursch J, Unterberg A, Wirtz CR. Epidermal growth factor receptor inhibition for the treatment of glioblastoma multiforme and other malignant brain tumours. Cancer Treat. Rev.32(2), 74–89 (2006).
   PubMed Web of Science ®Google Scholar
• Halatsch ME, Schmidt U, Botefur IC, Holland JF, Ohnuma T. Marked inhibition of glioblastoma target cell tumorigenicity in vitro by retrovirus-mediated transfer of a hairpin ribozyme against deletion-mutant epidermal growth factor receptor messenger RNA. J. Neurosurg.92(2), 297–305 (2000).
   PubMed Web of Science ®Google Scholar
• Shir A, Levitzki A. Inhibition of glioma growth by tumor-specific activation of double-stranded RNA-dependent protein kinase PKR. Nat. Biotechnol.20(9), 895–900 (2002).
   PubMedGoogle Scholar
• Fan QW, Weiss WA. RNA interference against a glioma-derived allele of EGFR induces blockade at G2M. Oncogene24(5), 829–837 (2005).
   PubMed Web of Science ®Google Scholar
• Facoetti A, Nano R, Zelini P et al. Human leukocyte antigen and antigen processing machinery component defects in astrocytic tumors. Clin. Cancer Res.11(23), 8304–8311 (2005).
   PubMed Web of Science ®Google Scholar
• Schartner JM, Hagar AR, Van Handel M, Zhang L, Nadkarni N, Badie B. Impaired capacity for upregulation of MHC class II in tumor-associated microglia. Glia51(4), 279–285 (2005).
   PubMed Web of Science ®Google Scholar
• Fecci PE, Mitchell DA, Whitesides JF et al. Increased regulatory T-cell fraction amidst a diminished CD4 compartment explains cellular immune defects in patients with malignant glioma. Cancer Res.66(6), 3294–3302 (2006).
   PubMed Web of Science ®Google Scholar
• Hussain SF, Kong LY, Jordan J et al. A novel small molecule inhibitor of signal transducers and activators of transcription 3 reverses immune tolerance in malignant glioma patients. Cancer Res.67(20), 9630–9636 (2007).
   PubMed Web of Science ®Google Scholar
• Huang PH, Mukasa A, Bonavia R et al. Quantitative analysis of EGFRvIII cellular signaling networks reveals a combinatorial therapeutic strategy for glioblastoma. Proc. Natl Acad. Sci. USA104(31), 12867–12872 (2007).
   PubMed Web of Science ®Google Scholar